



Curriculum Vitae

Personal information **Terhi Lehtinen**

Work experience

1. Employer: Finnish Medicines Agency
 - Start date: 092009
 - End date:
 - Position: Senior Medical Officer, PRAC alternate 2012-2015, PRAC delegate since Aug 2024
 - Activities: Assessment of postmarketing pharmacovigilance documentation including periodic safety update reports, risk management plans and performing of signal detection activities. Participation in Pharmacovigilance inspections.
 - Country: Finland
2. Employer: Clinical Research Services Turku, University of Turku
 - Start date: 102007
 - End date: 082009
 - Position: Research Director
 - Activities: Heading the clinical department. Principal investigator and responsible person for selected clinical studies.
 - Country: Finland
3. Employer: Clinical Research Services Turku, University of Turku
 - Start date: 032007
 - End date: 092007
 - Position: Clinical Investigator
 - Activities: Clinical Investigator for phase I and II studies. Protocol and study report writing. Preparation of clinical trial applications for ethics committee and regulatory authority. Participation in independent safety review boards.
 - Country: Finland
4. Employer: Remedium Oy/Encorium Oy
 - Start date: 092005
 - End date: 032007
 - Position: Director, Drug Safety
 - Activities: Responsible for the setting up and the development of pharmacovigilance services of the contract research organization.
 - Country: Finland
5. Employer: Schering Oy
 - Start date: 012003
 - End date: 092005
 - Position: Manager, Drug Safety
 - Activities: Heading the drug safety department.
 - Country: Finland
6. Employer: Schering Oy
 - Start date: 011999
 - End date: 042001
 - Position: Drug Safety Officer
 - Activities: Responsible for data entry, coding and medical assessment of individual SAE or ADR cases, preparation of Periodic Safety Update Reports for selected Products. Responsible for ongoing safety evaluation and safety query responses to regulatory authorities regarding selected products and studies.
 - Country: Finland
7. Employer: University of Turku
 - Start date: 121996
 - End date: 121998
 - Position: Assistant, medical biochemistry / PhD student
 - Activities: PhD student at the Postgraduate School of Health Sciences. Acting as assistant teacher in group exercises for medical biochemistry studies for medical students.
 - Country: Finland

Education and training

1. Subject: Finnish Medical Association
 - Start date: 2004
 - End date:
 - Qualification: Special competence in pharmaceutical medicine
 - Organisation:
 - Country: Finland
2. Subject: University of Turku
 - Start date: 1992
 - End date: 1998
 - Qualification: PhD
 - Organisation: Medical biochemistry
 - Country: Finland
3. Subject: University of Turku
 - Start date: 1990
 - End date: 1996
 - Qualification: MD

- Organisation:
- Country: Finland

Additional information

Publications

Peltonen JM, Pykkänen L, Jansen CT, Volanen I, Lehtinen T, Laihia JK, Leino L. Three Randomised Phase I/IIa Trials of 5% Cis-urocanic Acid Emulsion Cream in Healthy Adult Subjects and in Patients with Atopic Dermatitis. *Acta Dermato-Venereologica*. Epub ahead of print Nov 21, 2013 Lehtinen T, Tolonen A, Turpeinen M, Uusitalo J, Vuorinen J, Lammintausta R, Pelkonen O, Scheinin M. Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene. *Biopharm Drug Dispos*. 2013 34(7):387_95. Turpeinen M, Uusitalo J, Lehtinen T, Kailajärvi M, Pelkonen O, Vuorinen J, Tapanainen P, Stjernaschantz C, Lammintausta R, Scheinin M. Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo. *Int J Mol Sci*. 2013;14(7):14064_75. Kuoppamäki M, Sauramo A, Korpela K, Vahteristo M, Kailajärvi M, Lehtinen T, Ellmén J. Night_time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled_release levodopa/carbidopa. *Int J Clin Pharmacol Ther*. 2010 Nov;48(11):756_60. Vihinen P, Riikonen T, Laine A, Heino J. Integrin alpha 2 beta 1 in tumorigenic human osteosarcoma cell lines regulates cell adhesion, migration, and invasion by interaction with type I collagen. *Cell Growth Differ*. 1996;7(4):439_47. Riikonen T, Westermarck J, Koivisto L, Broberg A, Kähäri VM, Heino J. Integrin alpha 2 beta 1 is a positive regulator of collagenase (MMP_1) and collagen alpha 1(I) gene expression. *J Biol Chem*. 1995;270(22):13548_52. Riikonen T, Vihinen P, Potila M, Rettig W, Heino J. Antibody against human alpha 1 beta 1 integrin inhibits HeLa cell adhesion to laminin and to type I, IV, and V collagens. *Biochem Biophys Res Commun*. 1995;209(1):205_12. Riikonen T, Koivisto L, Vihinen P, Heino J. Transforming growth factor_beta regulates collagen gel contraction by increasing alpha 2 beta 1 integrin expression in osteogenic cells. *J Biol Chem*. 1995;270(1):376_82. Roivainen M, Piirainen L, Hovi T, Virtanen I, Riikonen T, Heino J, Hyypää T. Entry of coxsackievirus A9 into host cells: specific interactions with alpha v beta 3 integrin, the vitronectin receptor. *Virology*. 1994; 203(2):357_65. Santala P, Larjava H, Nissinen L, Riikonen T, Määttä A, Heino J. Suppressed collagen gene expression and induction of alpha 2 beta 1 integrin_type collagen receptor in tumorigenic derivatives of human osteogenic sarcoma (HOS) cell line. *J Biol Chem*. 1994; 269(2):1276_83.

Projects

Memberships

Other Relevant Information